Literature DB >> 9315482

DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors.

A J Ramsay1, K H Leong, I A Ramshaw.   

Abstract

Recent demonstrations of the immunogenicity of antigens encoded in DNA plasmids following delivery by various routes have heralded a new era in vaccine development. In this article, we review progress in DNA-based antiviral immunoprophylaxis. Preclinical studies have already established the immunogenicity of DNA plasmids encoding protective antigens from a wide variety of viral pathogens and work published in recent months has raised real prospects of broadly protective DNA vaccination against infections with influenza virus and HIV. We also describe a consecutive immunization protocol consisting of a priming dose of vaccine antigen encoded in DNA plasmids followed by a booster with the same antigen encoded in recombinant fowlpox virus vectors. We have used this strategy to generate protective antiviral cell-mediated immunity and sustained, high-level antibody responses both systemically and at mucosae, and to elucidate immunological mechanisms underlying the development of immunity to antigens delivered in DNA vectors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315482     DOI: 10.1038/icb.1997.60

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  16 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

3.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

Authors:  T Woodberry; J Gardner; L Mateo; D Eisen; J Medveczky; I A Ramshaw; S A Thomson; R A Ffrench; S L Elliott; H Firat; F A Lemonnier; A Suhrbier
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus.

Authors:  C J Dale; R De Rose; I Stratov; S Chea; D C Montefiori; S Thomson; I A Ramshaw; B E H Coupar; D B Boyle; M Law; S J Kent
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

7.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

8.  Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Eva Pérez-Jiménez; Juan Carlos Oliveros; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

9.  Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine.

Authors:  Diane E Webster; Michelle L Cooney; Zhongjun Huang; Damien R Drew; Ian A Ramshaw; Ian B Dry; Richard A Strugnell; Jenny L Martin; Steve L Wesselingh
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.